Sven Thormahlen
Keine laufenden Positionen mehr
Profil
Dr. Sven Thormahlen is Chief Technology Officer at Corbion NV.
He is on the Board of Directors at Accera, Inc.
Dr. Thormahlen was previously employed as Executive Vice President-Research & Development by Danone SA, Chief Executive Officer by MucoVax GmbH, Outside Director by Yakult Honsha Co., Ltd., and Senior Vice President-Research & Development by L'Oréal SA.
He received his graduate degree from the University of Hamburg and a doctorate degree from the University of Hamburg.
Ehemalige bekannte Positionen von Sven Thormahlen
Unternehmen | Position | Ende |
---|---|---|
MucoVax GmbH | Vorstandsvorsitzender | - |
CORBION N.V. | Technik-/Wissenschafts-/F&E-Leiter | - |
L'ORÉAL | Technik-/Wissenschafts-/F&E-Leiter | - |
Cerecin, Inc.
Cerecin, Inc. Pharmaceuticals: MajorHealth Technology Cerecin, Inc. develops therapies to treat central nervous system disorders. It offers therapeutic treatments for Parkinson's disease, Alzheimer's disease, and other age-related memory loss disorders. The firm is also developing therapies that address metabolic deficiencies and provide an alternative energy source for brain cells. The company was founded in 2001 and is headquartered in Boulder, CO. | Direktor/Vorstandsmitglied | - |
YAKULT HONSHA CO.,LTD. | Direktor/Vorstandsmitglied | - |
Ausbildung von Sven Thormahlen
University of Hamburg | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 4 |
---|---|
DANONE | Consumer Non-Durables |
L'ORÉAL | Consumer Non-Durables |
CORBION N.V. | Consumer Non-Durables |
YAKULT HONSHA CO.,LTD. | Consumer Non-Durables |
Private Unternehmen | 2 |
---|---|
Cerecin, Inc.
Cerecin, Inc. Pharmaceuticals: MajorHealth Technology Cerecin, Inc. develops therapies to treat central nervous system disorders. It offers therapeutic treatments for Parkinson's disease, Alzheimer's disease, and other age-related memory loss disorders. The firm is also developing therapies that address metabolic deficiencies and provide an alternative energy source for brain cells. The company was founded in 2001 and is headquartered in Boulder, CO. | Health Technology |
MucoVax GmbH |